drugset / Trial / NCT00369772

STAAR-1 Clinical Study

NCT00369772

Phase 4 Completed 2000 enrolled Amgen
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To assess the effect of Aranesp on the hemoglobin of CRI subjects who are recombinant human erythropoetin (rHuEPO)-naïve or converting from rHuEPO therapy

Timeline

Start
2002-02
Primary completion
Completion
2004-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Darbepoetin alfa Protein / enzyme biologic Subcutaneous